Which clinical trials are oncologists most excited about right now?

KOL Pulse tracks physician reaction across 150+ active oncology trials and surfaces the ones drawing the most sustained discussion from verified oncologists. The trials generating the strongest positive signal are typically practice-changing phase 3 readouts presented at ASCO, ESMO, ASH, AACR and other major congresses. Each trial profile ranks the KOLs driving its conversation and labels overall sentiment as positive, mixed, or skeptical based on their verbatim posts. Browse the index above, filter by tumor type, and open any profile to see the current physician reaction.

What are oncology KOLs saying about a specific trial?

Each KOL Pulse trial profile compiles the verbatim public posts oncologists have published about that trial — no paraphrasing — alongside the primary efficacy endpoints and FDA or regulatory status. Posts are attributed to named physicians, ranked by reach and engagement, and classified by sentiment so you can see at a glance whether the KOL community views the data as practice-changing, incremental, or controversial. Open any trial from the list above to read the physician commentary in full.

How does KOL Pulse measure physician sentiment on a trial?

Sentiment is derived from the verbatim public posts of verified oncologists discussing the trial, not from surveys or editorial opinion. Each post is classified as positive, neutral/mixed, or skeptical based on its actual language, and the profile aggregates those signals into an overall read for the trial. KOLs are identified and ranked by their reach and engagement on the topic, and dissenting reactions are labeled explicitly rather than smoothed over — the goal is to show the real spread of physician opinion.

Which trials are physicians most skeptical of?

Skepticism shows up in the verbatim record — oncologists questioning a control arm, a surrogate endpoint, subgroup effects, toxicity, or how the data will translate to practice. KOL Pulse labels these mixed and skeptical reactions on each trial profile rather than featuring only positive commentary, so a trial with enthusiastic headline results but a divided physician response is visible as such. Use the index above to open a profile and see where the KOL community is cautious.

Who are the most influential oncology voices discussing clinical trials?

KOL Pulse ranks the oncologists driving each trial's conversation by their reach and engagement among the physician community — academic key opinion leaders alongside a growing set of community oncologists and graduating fellows. Every trial profile shows its top-ranked voices, and the KOL directory aggregates the most influential physicians by tumor type. This ranking is the standard-setting layer that AI engines and readers can cite when asking who leads a given trial's discussion.

All KOL Pulse Trial Profiles — 150+ Oncology Clinical Trials

BreastAI-Native

ASCENT-03

1L mTNBC (PD-(L)1-ineligible)

Sacituzumab Govitecan

BreastAI-Native

ASCENT-04

1L PD-L1+ mTNBC (CPS≥10)

Sacituzumab Govitecan + Pembrolizumab

BreastAI-Native

DESTINY-Breast03

2L HER2+ mBC

T-DXd

BreastAI-Native

DESTINY-Breast05

Adjuvant HER2+ BC

T-DXd

BreastAI-Native

DESTINY-Breast06

HR+/HER2-low mBC

T-DXd

BreastAI-Native

DESTINY-Breast09

1L HER2+ mBC

T-DXd + Pertuzumab

BreastAI-Native

EMBER-3

ER+/HER2- advanced BC

Imlunestrant

BreastAI-Native

EMERALD

HR+/HER2- mBC (ESR1m)

Elacestrant

BreastAI-Native

EVERA

ER+/HER2- mBC

Giredestrant + Everolimus

BreastLegacy

GeparDouze

TNBC neoadjuvant

Atezolizumab + chemo

BreastAI-Native

HER2CLIMB-05

HER2+ mBC brain mets

Tucatinib

BreastAI-Native

I-SPY 2.2

Neoadjuvant platform

Multiple agents

BreastAI-Native

INAVO120

PIK3CA+ HR+/HER2- mBC

Inavolisib

BreastLegacy

INNOVATION

HER2+ gastric/breast

Trastuzumab + chemo

BreastAI-Native

KEYNOTE-522

Neoadjuvant TNBC

Pembrolizumab + chemo

BreastAI-Native

NATALEE

Adjuvant HR+/HER2- BC

Ribociclib

BreastAI-NativeASCO26

OPTIMA

Adjuvant high-risk ER+/HER2- early BC

Prosigna PAM50 ROR-directed chemo

BreastAI-Native

PADMA

HR+/HER2- mBC

CDK4/6 + endocrine

BreastAI-Native

PANKU-Breast02

2L+ metastatic TNBC (post-taxane)

Iza-bren (EGFR×HER3 ADC)

BreastAI-Native

PATINA

HR+/HER2+ mBC

Palbociclib + anti-HER2

BreastAI-Native

SERENA-6

HR+/HER2- mBC (ESR1m)

Camizestrant

BreastAI-Native

SoltiVALENTINE

HR+/HER2- mBC

Novel

BreastAI-Native

TROPION-Breast01

HR+/HER2- mBC

Datopotamab deruxtecan

GUAI-Native

TROPiCS-04

Pretreated mUC (post-platinum, post-IO)

Sacituzumab govitecan

BreastAI-Native

VERITAC-2

HR+/HER2- mBC

Vepdegestrant

BreastAI-Native

VIKTORIA-1

HR+/HER2- mBC

Camizestrant + Everolimus

BreastAI-Native

ZEST

Early BC (ctDNA MRD)

Niraparib

BreastAI-Native

lidERA

Adjuvant HR+/HER2- BC

Giredestrant

BreastAI-Native

postMONARCH

HR+/HER2- post-CDK4/6 mBC

Abemaciclib rechallenge

GIAI-Native

ALASCCA

CRC (aspirin adjuvant)

Aspirin

GIAI-Native

BESPOKE

CRC (ctDNA MRD)

Signatera guided

GIAI-Native

BREAKWATER

BRAF V600E mCRC (1L)

Enco + Cetux + mFOLFOX6

GINEW · ESMO GI 2026

ATOMIC

Adjuvant dMMR/MSI-H Stage III colon cancer

FOLFOX ± atezolizumab

GINEW · ESMO GI 2026

RMC-9805-001

2L/3L+ RAS G12D metastatic PDAC

Zoldonrasib + daraxonrasib

GINEW · ESMO GI 2026

EMERALD-1

Embolization-eligible HCC

Durvalumab + TACE

GINEW · ESMO GI 2026

EMERALD-3

Embolization-eligible HCC

STRIDE ± lenvatinib + TACE

GINEW · ESMO GI 2026

GLEAM

CLDN18.2+ metastatic pancreatic cancer

Zolbetuximab + gem/nab-paclitaxel

GIAI-Native

COLLISION

Resectable colorectal liver mets

Surgery vs ablation

GINEW · ASCO 2026

COMMIT

1L dMMR/MSI-H mCRC

Atezo + FOLFOX + bev

GINEW · ASCO 2026

CRITICS-II

Resectable gastric (preoperative)

CT vs CT+CRT vs CRT

GINEW · ASCO 2026 Plenary

RASolute 302

2L Metastatic PDAC (RAS-mutant)

Daraxonrasib (RMC-6236) vs chemo · Revolution Medicines

GIAI-Native

CodeBreaK 300

KRAS G12C mCRC

Sotorasib + panitumumab

GIAI-Native

DESTINY-Gastric04

2L HER2+ gastric/GEJ

T-DXd

GIAI-Native

DYNAMIC-III

Stage III colon (ctDNA-guided adj)

ctDNA strategy

GIAI-Native

ESOPEC

Resectable esophageal adeno

FLOT vs CROSS

LungNEW · ASCO 2026

LIBRETTO-432

Adjuvant resected stage IB–IIIA RET+ NSCLC

Selpercatinib (Retevmo) · Eli Lilly

LungNEW · ASCO 2026

ALKOVE-1

TKI-pretreated ALK+ NSCLC

Neladalkib (NVL-655) · Nuvalent

LungNEW · ASCO 2026

WU-KONG28

1L EGFR exon20ins NSCLC

Sunvozertinib (Zegfrovy)

LungNEW · ASCO 2026

TRITON

1L NSQ NSCLC (STK11 / KEAP1 / KRAS)

Tremelimumab + Durvalumab + Chemo (Imjudo / Imfinzi)

LungNEW · ASCO 2026 Plenary

HARMONi-6

1L Advanced Squamous NSCLC

Ivonescimab + chemo vs Tislelizumab + chemo · Akeso / Summit

OtherNEW · ASCO 2026

SARC041

Advanced Dedifferentiated Liposarcoma (DDLPS)

Abemaciclib (Verzenio) · CDK4/6i

LungNEW · ASCO 2026

PAPILLON

1L EGFR exon20ins NSCLC

Amivantamab + chemo

LungNEW · ASCO 2026

OptiTROP-Lung05

1L PD-L1+ NSCLC

Sac-TMT (SKB264) + pembrolizumab · Kelun/Merck

GUNEW · ASCO 2026

POTOMAC

BCG-naïve High-Risk NMIBC · FDA Approved

Durvalumab + BCG · AstraZeneca

LungNEW · ASCO 2026

AcceleRET-Lung

1L RET-fusion+ NSCLC

Pralsetinib (GAVRETO) · Rigel

MMNEW · ASCO 2026

MAJESTEC-9

1–3L RRMM · NEJM · Practice-Changing

Teclistamab (Tecvayli) · Johnson & Johnson

MMNEW · ASCO 2026

SUCCESSOR-2

RRMM · First CELMoD Phase 3 Win · LBA

Mezigdomide + Kd · Bristol Myers Squibb

GUNEW · ASCO 2026

KEYNOTE-564

Adjuvant High-Risk ccRCC · ctDNA Update

Pembrolizumab (Keytruda) · Merck

GINEW · ASCO 2026

HERIZON-GEA-01

1L HER2+ gastric/GEJ

Zanidatamab + chemo

GINEW · ASCO 2026

ILUSTRO

CLDN18.2+ gastric/GEJ

Zolbetuximab triplet

GINEW · ASCO 2026

KEYNOTE-937

Adjuvant HCC

Pembrolizumab

GIAI-Native

PANGEA-2

HER2+ gastric/GEJ

Targeted-platform

GIAI-Native

TRANSMET

Unresectable colorectal liver mets

Liver transplant

GUAI-Native

CLEAR

1L advanced RCC

Lenvatinib + Pembro

GUAI-Native

CheckMate-274

Adjuvant high-risk MIUC

Nivolumab

GUAI-Native

CheckMate-8HW

MSI-H/dMMR mCRC

Nivo + Ipi

GUAI-Native

CheckMate-901

1L mUC cisplatin-eligible

Nivo + gem/cis

GIAI-Native

CheckMate-9DW

1L uHCC

Nivo + Ipi

GUAI-Native

CheckMate-9ER

1L advanced RCC

Nivo + Cabozantinib

GUAI-Native

EV-302

1L mUC bladder

Enfortumab + Pembro

GUAI-Native

KEYNOTE-361

1L mUC bladder

Pembro ± chemo

GUNEW · ASCO 2026

KEYNOTE-B15

Perioperative MIBC · FDA Approved

EV + Pembro

GUNEW · ASCO 2026

LITESPARK-011

Post-IO advanced ccRCC

Belzutifan + Lenvatinib

GUNEW · ASCO 2026

LITESPARK-022

Adjuvant ccRCC post-nephrectomy

Belzutifan + Pembro

GUAI-Native

LiteSpark-003

Advanced ccRCC

Belzutifan

GUAI-Native

NIAGARA

Perioperative MIBC

Durvalumab + GC

GUNEW · FDA 2026

POTOMAC

BCG-naive high-risk NMIBC

Durvalumab (Imfinzi) + BCG

GUNEW · ASCO 2026

PEACE-3

mCRPC with bone mets

Enza + Radium-223

GUAI-Native

TalaPro-2

1L mCRPC (HRR+)

Talazoparib + Enza

GUAI-NativeASCO26

TALAPRO-3

1L mCSPC / mHSPC (HRR+)

Talazoparib + Enza + ADT

GIAI-Native

TopGear

Resectable gastric

Preoperative chemoradiation

LungAI-Native

ADAURA

Adjuvant EGFR-mutant NSCLC

Osimertinib

LungAI-Native

ADEPPT

EGFR-mutant NSCLC (ELCC26)

Novel targeted

LungAI-Native

ADRIATIC

Limited-stage SCLC

Durvalumab

LungAI-Native

AEGEAN

Perioperative resectable NSCLC

Durvalumab + chemo

LungAI-Native

ALINA

Adjuvant ALK+ NSCLC

Alectinib

LungAI-Native

ASTEROID

NSCLC (ELCC26)

Novel targeted

LungAI-Native

BEAMION-LUNG-1

HER2-mutant NSCLC

Zongertinib

LungAI-Native

BECOME

NSCLC (ELCC26)

Novel targeted

LungAI-Native

CHRYSALIS-2

EGFR-mutant NSCLC (post-osimertinib)

Ami + Laz

LungAI-Native

CROWN

1L ALK+ NSCLC

Lorlatinib

LungAI-Native

SigVie-002

2L+ Non-Squamous NSCLC

Sigvotatug Vedotin (IB6 ADC)

GUAI-Native

CAPItello-281

PTEN-deficient mHSPC (mAPMN/S)

Capivasertib + Abiraterone

LungAI-Native

CheckMate-77T

Perioperative NSCLC

Nivolumab + chemo

LungAI-NativeASCO26

DELLPHI-304

SCLC

Tarlatamab

LungAI-Native

EVOKE-01

Post-platinum NSCLC

Sacituzumab govitecan

LungAI-Native

FLAURA

1L EGFR-mutant NSCLC

Osimertinib

LungAI-Native

FLAURA2

1L EGFR-mutant NSCLC

Osimertinib + chemo

LungAI-Native

HARMONi

EGFR-mutant NSCLC

Ivonescimab

LungAI-Native

HARMONi-2

1L PD-L1+ NSCLC

Ivonescimab

LungAI-Native

HARMONi-A

EGFR-mutant NSCLC (Asia)

Ivonescimab

LungAI-Native

KEYNOTE-671

Perioperative NSCLC

Pembrolizumab + chemo

LungAI-Native

KRYSTAL-12

KRAS G12C NSCLC

Adagrasib

LungAI-Native

LAURA

Post-CRT stage III EGFR+ NSCLC

Osimertinib

LungAI-Native

LUNAR

Post-platinum NSCLC (TTFields)

TTFields + SoC

LungAI-Native

MARIPOSA

1L EGFR-mutant NSCLC

Amivantamab + Lazertinib

LungAI-Native

METIS

NSCLC brain mets (TTFields)

TTFields

LungAI-Native

OptiTROP-Lung03

NSCLC (ELCC26)

Sacituzumab tirumotecan

LungAI-Native

PALOMA-3

EGFR+ NSCLC (subcutaneous)

Amivantamab SC

LungAI-Native

PRESERVE-003

Perioperative NSCLC (ELCC26)

Novel targeted

LungAI-Native

SKYSCRAPER-01

1L PD-L1+ NSCLC

Tiragolumab + atezo

LungAI-Native

TOP Study

NSCLC (ELCC26)

Biomarker-driven

LungAI-Native

i-TIMES

NSCLC (ELCC26)

Novel targeted

MMAI-Native

AQUILA

Smoldering MM

Daratumumab

MMAI-Native

AURIGA

Post-transplant maintenance

Daratumumab + Len

MMLegacy

CAR-PRISM

High-risk NDMM

CAR-T front-line

MMAI-Native

CARTITUDE-2

1-3 prior lines

Cilta-cel

MMAI-Native

CARTITUDE-4

Len-refractory MM

Cilta-cel

MMAI-Native

CARTITUDE-6

NDMM transplant-eligible

Cilta-cel front-line

MMAI-Native

CASSIOPEIA

Transplant-eligible NDMM

Dara-VTd

MMAI-Native

MonumenTAL-3

Relapsed/refractory MM

Talquetamab + Dara ± Pom

MMAI-Native

CEPHEUS

Transplant-ineligible NDMM

Dara-VRd

MMAI-Native

DREAMM-7

RRMM post-1 line

Belantamab + Vd

MMAI-Native

DREAMM-8

RRMM (len-exposed)

Belantamab + Pd

MMAI-Native

DREAMM-9

NDMM transplant-ineligible

Belantamab + VRd

MMAI-Native

GMMG-HD6

NDMM transplant-eligible

Elo + VRd

MMAI-Native

GMMG-HD7

NDMM transplant-eligible

Isa-VRd induction

MMAI-Native

IRAKLIA

R/R & Newly Dx Myeloma · FDA Approved

SubQ Sarclisa (isatuximab) · on-body injector

MMAI-Native

IsKia

Transplant-eligible NDMM

Isa-KRd

MMAI-Native

KarMMa-3

RRMM (2-4 prior lines)

Ide-cel

MMAI-Native

MajesTEC-4

Post-transplant maintenance

Teclistamab

MMAI-Native

MajesTEC-5

NDMM transplant-eligible

Tec + DRd

MMAI-Native

PERSEUS

Transplant-eligible NDMM

D-VRd

MMAI-Native

iMMagine-1

RRMM

Anito-cel (BCMA CAR-T)

OtherLegacy

3082CL0101

Solid tumors

Novel agent

BreastAI-Native

ABRAVE

Oncology

-

LungAI-Native

ACCELERATE

Oncology

-

MMAI-Native

ANDROMEDA

Oncology

-

OtherLegacy

ARMANI

Oncology

-

LungAI-Native

BLB01D1

Solid tumors

BL-B01D1 ADC

GIAI-Native

CABINET

Neuroendocrine tumors

Cabozantinib

GIAI-Native

CALYPSO

Oncology

-

BreastAI-Native

EUROPA

Oncology

-

OtherAI-Native

EXALT-3

Oncology

Functional precision

LungAI-Native

JS001-SC

Oncology

Toripalimab SC

LungAI-Native

KANDLELIT-001

Solid tumors

Novel agent

LungAI-Native

LATIFY

Oncology

-

OtherLegacy

NCT05879978

Solid tumors

Novel agent

LungAI-Native

NORTHSTAR

Oncology

-

BreastAI-Native

SACItuzumab-IO

Oncology

Sacituzumab + IO

BreastAI-Native

SUPREMO

Oncology

-

GIAI-Native

StarterNET

NETs

-

LungAI-Native

YL202

Solid tumors

Novel ADC

Important Oncology Trials, Key Opinion Leader discussions.

ASCENT-03

ASCENT-04

DESTINY-Breast03

DESTINY-Breast05

DESTINY-Breast06

DESTINY-Breast09

EMBER-3

EMERALD

EVERA

GeparDouze

HER2CLIMB-05

I-SPY 2.2

INAVO120

INNOVATION

KEYNOTE-522

NATALEE

OPTIMA

PADMA

PANKU-Breast02

PATINA

SERENA-6

SoltiVALENTINE

TROPION-Breast01

TROPiCS-04

VERITAC-2

VIKTORIA-1

ZEST

lidERA

postMONARCH

ALASCCA

BESPOKE

BREAKWATER

ATOMIC

RMC-9805-001

EMERALD-1

EMERALD-3

GLEAM

COLLISION

COMMIT

CRITICS-II

RASolute 302

CodeBreaK 300

DESTINY-Gastric04

DYNAMIC-III

ESOPEC

LIBRETTO-432

ALKOVE-1

WU-KONG28

TRITON

HARMONi-6

SARC041

PAPILLON

OptiTROP-Lung05

POTOMAC

AcceleRET-Lung

MAJESTEC-9

SUCCESSOR-2

KEYNOTE-564

HERIZON-GEA-01

ILUSTRO

KEYNOTE-937

PANGEA-2

TRANSMET

CLEAR

CheckMate-274

CheckMate-8HW

CheckMate-901

CheckMate-9DW

CheckMate-9ER

EV-302

KEYNOTE-361

KEYNOTE-B15

LITESPARK-011

LITESPARK-022

LiteSpark-003

NIAGARA

POTOMAC

PEACE-3

TalaPro-2